Buch, Englisch, 93 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 207 g
Buch, Englisch, 93 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 207 g
ISBN: 978-981-1380-21-1
Verlag: Springer Nature Singapore
The book explores the potential use of these inhibitors as novel therapeutic agents, considers the current challenges involved in using them to tackle neurological complications, and offers a novel solution by designing isoform-selective inhibitors and employing combinatorial therapeutic strategies. Its final section, which explores future directions, elaborates on the possibility of enhancing HDAC inhibitors’ therapeutic efficacy against various neurological complications.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft
- Interdisziplinäres Wissenschaften Wissenschaften Interdisziplinär Neurowissenschaften, Kognitionswissenschaft
- Naturwissenschaften Biowissenschaften Biowissenschaften Genetik und Genomik (nichtmedizinisch)
- Naturwissenschaften Biowissenschaften Proteinforschung
Weitere Infos & Material
Chapter 1. Role of Epigenetics in neurological diseases.- Chapter 2. Epigenetic enzymes and the drawbacks of conventional therapeutic regimens.- Chapter 3. Distinct classes of HDACs.- Chapter 4. HDAC implications in neurological diseases.- Chapter 5. HDAC inhibitors and their structurally distinct groups.- Chapter 6. HDAC inhibitors as novel therapeutic option against therapeutically challenging neurological disorders.- Chapter 7. Current Challenges with HDAC inhibitor based therapeutic intervention against neurological maladies.- Chapter 8. Escalating need of isoform selective inhibitors for enhanced therapeutic efficacy.- Chapter 9. Combinatorial therapeutic regimens using HDAC inhibitors in conjunction with conventional therapeutic agents.- Chapter 10. Future directions of epigenetic research in tackling neurological complications.